Browse KRT17

Summary
SymbolKRT17
Namekeratin 17, type I
Aliases PCHC1; keratin 17; 39.1; CK-17; K17; cytokeratin-17; keratin-17; Keratin, type I cytoskeletal 17
Chromosomal Location17q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm
Domain PF00038 Intermediate filament protein
Function

Type I keratin involved in the formation and maintenance of various skin appendages, specifically in determining shape and orientation of hair (By similarity). Required for the correct growth of hair follicles, in particular for the persistence of the anagen (growth) state (By similarity). Modulates the function of TNF-alpha in the specific context of hair cycling. Regulates protein synthesis and epithelial cell growth through binding to the adapter protein SFN and by stimulating Akt/mTOR pathway (By similarity). Involved in tissue repair. May be a marker of basal cell differentiation in complex epithelia and therefore indicative of a certain type of epithelial "stem cells". Acts as a promoter of epithelial proliferation by acting a regulator of immune response in skin: promotes Th1/Th17-dominated immune environment contributing to the development of basaloid skin tumors (By similarity). May act as an autoantigen in the immunopathogenesis of psoriasis, with certain peptide regions being a major target for autoreactive T-cells and hence causing their proliferation.

> Gene Ontology
 
Biological Process GO:0001558 regulation of cell growth
GO:0001942 hair follicle development
GO:0006417 regulation of translation
GO:0008544 epidermis development
GO:0009913 epidermal cell differentiation
GO:0010608 posttranscriptional regulation of gene expression
GO:0016049 cell growth
GO:0022404 molting cycle process
GO:0022405 hair cycle process
GO:0030216 keratinocyte differentiation
GO:0030307 positive regulation of cell growth
GO:0031069 hair follicle morphogenesis
GO:0031424 keratinization
GO:0034248 regulation of cellular amide metabolic process
GO:0034250 positive regulation of cellular amide metabolic process
GO:0042303 molting cycle
GO:0042633 hair cycle
GO:0042634 regulation of hair cycle
GO:0042635 positive regulation of hair cycle
GO:0043588 skin development
GO:0045103 intermediate filament-based process
GO:0045104 intermediate filament cytoskeleton organization
GO:0045109 intermediate filament organization
GO:0045682 regulation of epidermis development
GO:0045684 positive regulation of epidermis development
GO:0045727 positive regulation of translation
GO:0045927 positive regulation of growth
GO:0048730 epidermis morphogenesis
GO:0051797 regulation of hair follicle development
GO:0051798 positive regulation of hair follicle development
GO:0098773 skin epidermis development
Molecular Function GO:0005200 structural constituent of cytoskeleton
GO:0032395 MHC class II receptor activity
GO:0042287 MHC protein binding
GO:0042289 MHC class II protein binding
Cellular Component GO:0005882 intermediate filament
GO:0045111 intermediate filament cytoskeleton
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1266738: Developmental Biology
R-HSA-6805567: Keratinization
Summary
SymbolKRT17
Namekeratin 17, type I
Aliases PCHC1; keratin 17; 39.1; CK-17; K17; cytokeratin-17; keratin-17; Keratin, type I cytoskeletal 17
Chromosomal Location17q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between KRT17 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between KRT17 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
20871598Skin Basal Cell CarcinomaInhibit immunity (T cell function)We here show that genetic ablation of keratin 17 (Krt17) protein, which is induced in basaloid skin tumors and co-polymerizes with Krt5 in vivo, delays basaloid follicular hamartoma tumor initiation and growth in mice with constitutive Hh signaling in epidermis. This delay is preceded by a reduced inflammation and a polarization of inflammatory cytokines from a Th1- and Th17-dominated profile to a Th2-dominated profile. Re-expression of Krt17 in Gli2(tg); Krt17(-/-) keratinocytes induces select Th1 chemokines that have established roles in BCC.
Summary
SymbolKRT17
Namekeratin 17, type I
Aliases PCHC1; keratin 17; 39.1; CK-17; K17; cytokeratin-17; keratin-17; Keratin, type I cytoskeletal 17
Chromosomal Location17q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of KRT17 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolKRT17
Namekeratin 17, type I
Aliases PCHC1; keratin 17; 39.1; CK-17; K17; cytokeratin-17; keratin-17; Keratin, type I cytoskeletal 17
Chromosomal Location17q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of KRT17 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.9440.355
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.7450.659
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)872.1950.103
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2360.739
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.2180.943
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.8150.827
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-1.4520.211
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-2.460.141
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.4570.795
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.860.429
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.1140.935
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.5820.06
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of KRT17 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolKRT17
Namekeratin 17, type I
Aliases PCHC1; keratin 17; 39.1; CK-17; K17; cytokeratin-17; keratin-17; Keratin, type I cytoskeletal 17
Chromosomal Location17q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of KRT17. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolKRT17
Namekeratin 17, type I
Aliases PCHC1; keratin 17; 39.1; CK-17; K17; cytokeratin-17; keratin-17; Keratin, type I cytoskeletal 17
Chromosomal Location17q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of KRT17. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by KRT17.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolKRT17
Namekeratin 17, type I
Aliases PCHC1; keratin 17; 39.1; CK-17; K17; cytokeratin-17; keratin-17; Keratin, type I cytoskeletal 17
Chromosomal Location17q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of KRT17. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolKRT17
Namekeratin 17, type I
Aliases PCHC1; keratin 17; 39.1; CK-17; K17; cytokeratin-17; keratin-17; Keratin, type I cytoskeletal 17
Chromosomal Location17q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of KRT17 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolKRT17
Namekeratin 17, type I
Aliases PCHC1; keratin 17; 39.1; CK-17; K17; cytokeratin-17; keratin-17; Keratin, type I cytoskeletal 17
Chromosomal Location17q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between KRT17 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolKRT17
Namekeratin 17, type I
Aliases PCHC1; keratin 17; 39.1; CK-17; K17; cytokeratin-17; keratin-17; Keratin, type I cytoskeletal 17
Chromosomal Location17q21.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting KRT17 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.